Keyword: EuroBiotech Report
In this week's EuroBiotech Report, MorphoSys lands Incyte deal, Adaptimmune teams with Astellas and Galapagos bags fibrosis options.
In our EuroBiotech roundup this week, Keytruda combo trial advances, Theranexus seeks Alzheimer’s partner and Medicxi releases funding tranche.
The deal comes one year after Galapagos landed global rights to an early-stage idiopathic pulmonary fibrosis treatment in development at Fibrocor.
The agreement sees Astellas pay $50 million upfront to work with Adaptimmune to identify targets and develop cell therapies against them.
The deal, which features a $150 million equity investment and up to $1.1 billion in milestones, gives Incyte a stake in a near-approval CAR-T killer.
In this week's EuroBiotech Report, NorthSea raises cash for NASH trial, Boehringer buys fibrosis assets and AstraZeneca forms metabolic disease pact.
In our EuroBiotech roundup this week, Newron plots path back for evenamide, Oxurion posts diabetic macular edema data and Sotio opens Basel office.
Boehringer is swallowing Enleofen’s anti-IL-11 antibody platform, putting it on the hook for up to $1 billion in milestones per product.
The financing comes months after NorthSea enrolled the first NASH patient in the trial of its structurally engineered fatty acid icosabutate.
The agreement gives AstraZeneca the option to negotiate a license for saRNA molecules after getting a look at preclinical data on the candidates.